Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

NCT07187856 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of the experimental drug PG-102 compared to a placebo and the approved drug semaglutide in adults with type 2 diabetes.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 80 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2026-01 · est. completion 2026-12

Where 1 site · Australia

What this study is testing ClinicalTrials.gov NCT07187856 ↗

Description as written by the study sponsor.

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

Treatments tested

PG-102 Drug

PG-102 is administered subcutaneously once weekly with a titration regimen.
Placebo Drug

Placebo is administered subcutaneously once weekly.
Semaglutide Drug

Open-label semaglutide is administered subcutaneously once weekly with titration regimen.

Main thing measured	Absolute change in HbA1c From Baseline at Week 24
Sponsor	ProGen. Co., Ltd.
Conditions studied	Type 2 Diabetes Mellitus (T2DM)
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07187856 ↗